Jim Cramer Expects Palantir To Reach New All-Time High

Jim Cramer reiterated his $200 price target for Palantir Technologies (PLTR) amidst recent positive corporate developments and a 0.8% share increase, while advising against Viking Therapeutics (VKTX), which saw a 1.2% decline following its Phase 2 trial data release. Separately, he characterized Richtech Robotics (RRR) as a highly speculative buy, cautioning on the risk of total loss after its $100 million at-the-market offering, as RRR shares fell 5.2%.

Analysis

Divergent analyst sentiment highlights varying risk profiles across technology and biotech sectors. Palantir Technologies (PLTR) received a strong endorsement with a reiterated $200 price target, supported by fundamental developments including a five-year contract extension with Lear Corp. and a new collaboration with Lumen Technologies, which contributed to a 0.8% share price increase to $156.14. In sharp contrast, Viking Therapeutics (VKTX) faced a negative outlook following the release of its Phase 2 trial data for the GLP-1/GIP agonist VK2735. This skepticism was reflected in the market as its shares fell 1.2% to $26.53 amid a noted "downward bias." Separately, Richtech Robotics (RRR) was characterized as a purely speculative asset with a high risk of total loss. This cautionary stance is underscored by the company's recent announcement of a $100 million at-the-market offering, a dilutive event that likely contributed to the stock's 5.2% decline to $2.54.

Key Decisions for Investors

• For Palantir (PLTR), the combination of a major contract extension, a new corporate collaboration, and a reiterated high price target may reinforce a bullish thesis, with the upcoming AIPCon 8 event serving as a potential near-term catalyst to monitor.
• Investors should exercise caution with Viking Therapeutics (VKTX), as the negative analyst sentiment and price decline following its Phase 2 data release signal significant uncertainty and potential headwinds for its key drug candidate.
• Richtech Robotics (RRR) should be viewed as a high-risk, speculative position; the recent announcement of a $100 million at-the-market offering presents substantial dilution risk, validating the analyst's warning that invested capital could be subject to total loss.